Clinical Trial Update: Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and glucodynamic crossover study evaluating subcutaneously administered insulin lispro with recombinant human hyaluronidase (rHuPH20) an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Recombinant human hyaluronidase (rHuPH20) (recombinant human hyaluronidase)
• insulin lispro (insulin lispro)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2014-07-11